Therapy Areas: Oncology
Calidi Biotherapeutics announces Series A Investments
22 January 2020 -

Immuno-oncology company Calidi Biotherapeutics Inc said on Tuesday that it has completed Series A investments with two South Korean firms Won & Partners and Greentable Co Ltd.

This financing was led by Heehyoung Lee, PhD, co-founder and managing partner of LumeBio, advisor to Calidi Biotherapeutics and a veteran in the biopharmaceutical space.

The Series A investments will be used by Calidi to advance manufacturing in preparation for its pre-IND and IND filings. It is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.

Previously, Dr Lee has held positions at Hanmi Pharmaceuticals, Sorrento Therapeutics and City of Hope.

Login
Username:

Password: